<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02509624</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-223-1018</org_study_id>
    <secondary_id>2015-002444-14</secondary_id>
    <nct_id>NCT02509624</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Pharmacokinetics of Selonsertib in Participants With Normal and Impaired Hepatic Function</brief_title>
  <official_title>A Phase 1, Open-Label, Parallel-Group, Single Dose Study to Evaluate the Pharmacokinetics of GS-4997 in Subjects With Normal and Impaired Hepatic Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the pharmacokinetics (PK) of selonsertib&#xD;
      in participants with impaired hepatic function relative to matched, healthy controls.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 18, 2015</start_date>
  <completion_date type="Actual">December 15, 2015</completion_date>
  <primary_completion_date type="Actual">December 15, 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic (PK) Parameter: AUCinf of Selonsertib and Its Metabolite GS-607509</measure>
    <time_frame>0 (predose), 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96, and 120 hours postdose on Day 1. Additional PK samples were collected at the Day 10 and 14 follow-up visits approximately the same time as the Day 1 predose sample.</time_frame>
    <description>AUCinf is defined as the concentration of drug extrapolated to infinite time.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK Parameter: AUClast of Selonsertib and Its Metabolite GS-607509</measure>
    <time_frame>0 (predose), 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96, and 120 hours postdose on Day 1. Additional PK samples were collected at the Day 10 and 14 follow-up visits approximately the same time as the Day 1 predose sample.</time_frame>
    <description>AUClast is defined as the concentration of drug from time zero to the last observable concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK Parameter: Cmax of Selonsertib and Its Metabolite GS-607509</measure>
    <time_frame>0 (predose), 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96, and 120 hours postdose on Day 1. Additional PK samples were collected at the Day 10 and 14 follow-up visits approximately the same time as the Day 1 predose sample.</time_frame>
    <description>Cmax is defined as the maximum concentration of drug.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Experiencing Treatment-Emergent Study Drug-related Adverse Events (AEs)</measure>
    <time_frame>Day 1 plus 30 days</time_frame>
    <description>An AE was any untoward medical occurrence in a clinical study participant which did not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Treatment-emergent AEs were defined as events that met one of the following criteria: 1) Any AEs with an onset date of on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug; or 2) Any AEs leading to premature discontinuation of study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Experiencing Any Treatment-Emergent and Grade ≥ 3 Laboratory Abnormalities</measure>
    <time_frame>Day 1 plus 30 days</time_frame>
    <description>Treatment-emergent laboratory abnormalities were defined as values that increased at least 1 toxicity grade from predose at any postdose visit, up to and including the date of last dose of study drug plus 30 days for participants who permanently discontinued study drug. If the relevant baseline laboratory value was missing, then any abnormality of at least Grade 1 observed within the time frame specified above was considered treatment-emergent. Severity grades were defined based on modified Common Terminology Criteria for Adverse Events (CTCAE) Laboratory Abnormality and Adverse Event Severity Grading, where 1=Mild, 2=Moderate, 3=Severe, 4=Potentially Life Threatening. The most severe graded abnormality from all tests was counted for each participant.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Diabetic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>Moderate hepatic impairment (Cohort 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with moderate hepatic impairment and matched healthy controls will receive a single dose of selonsertib on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Severe hepatic impairment (Cohort 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with severe hepatic impairment and matched healthy controls will receive a single dose of selonsertib on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mild hepatic impairment (Cohort 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with mild hepatic impairment and matched healthy controls will receive a single dose of selonsertib on Day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Selonsertib</intervention_name>
    <description>6 mg tablets administered orally in fed state</description>
    <arm_group_label>Mild hepatic impairment (Cohort 3)</arm_group_label>
    <arm_group_label>Moderate hepatic impairment (Cohort 1)</arm_group_label>
    <arm_group_label>Severe hepatic impairment (Cohort 2)</arm_group_label>
    <other_name>GS-4997</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
        All participants:&#xD;
&#xD;
          -  Body mass index (BMI) from 18 to 40 kg/m^2, inclusive at study screening&#xD;
&#xD;
          -  Creatinine clearance (CrCl) ≥ 60 mL/min (using the Cockcroft-Gault method) based on&#xD;
             serum creatinine and actual body weight as measured at screening&#xD;
&#xD;
        Participants with impaired hepatic function:&#xD;
&#xD;
          -  Aside from hepatic insufficiency, participants must be sufficiently healthy for study&#xD;
             participation based upon screening evaluations.&#xD;
&#xD;
          -  Must have diagnosis of chronic (&gt; 6 months), stable hepatic impairment with no&#xD;
             clinically significant change in hepatic status within the 3 months (90 days) prior to&#xD;
             study drug administration (Day 1).&#xD;
&#xD;
          -  Participants with severe hepatic impairment must have a score on the&#xD;
             Child-Pugh-Turcotte scale of 10-15 at screening.&#xD;
&#xD;
          -  Participants with moderate hepatic impairment must have a score on the&#xD;
             Child-Pugh-Turcotte scale of 7-9 at screening.&#xD;
&#xD;
          -  Participants with mild hepatic impairment must have a score on the Child-Pugh-Turcotte&#xD;
             scale of 5-6 at screening.&#xD;
&#xD;
        Healthy participants (matched control):&#xD;
&#xD;
          -  Must be in good health based upon screening evaluations.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
        All participants:&#xD;
&#xD;
          -  Pregnant or lactating females&#xD;
&#xD;
          -  Have received any investigational compound or device within 30 days prior to study&#xD;
             dosing&#xD;
&#xD;
          -  Current alcohol or substance abuse&#xD;
&#xD;
          -  A positive test result for human immunodeficiency virus (HIV-1/2) antibody&#xD;
&#xD;
          -  Have poor venous access that limits phlebotomy&#xD;
&#xD;
          -  Have been treated with systemic steroids, anti-HIV agents, immunosuppressant&#xD;
             therapies, or chemotherapeutic agents within 3 months prior to screening or expected&#xD;
             to receive these agents during the study (eg, corticosteroids, immunoglobulins, and&#xD;
             other immune- or cytokine-based therapies) that would be contraindicated for other&#xD;
             exclusion criteria.&#xD;
&#xD;
          -  Significant serious skin disease, such as but not limited to rash, food allergy,&#xD;
             eczema, psoriasis, or urticaria&#xD;
&#xD;
          -  Significant drug sensitivity or drug allergy (such as anaphylaxis or hepatoxicity)&#xD;
&#xD;
          -  Unstable cardiac disease, including history of myocardial infarction within 1 year of&#xD;
             screening, recurrent episodes of ventricular tachycardia despite appropriate medical&#xD;
             therapy, decompensated congestive heart failure, or dilated cardiomyopathy with left&#xD;
             ventricular ejection fraction &lt; 40%, or a family history of Long QT Syndrome, or&#xD;
             unexplained death in an otherwise healthy participants between the ages of 1 and 30&#xD;
             years.&#xD;
&#xD;
          -  Syncope, palpitations, or unexplained dizziness&#xD;
&#xD;
          -  Implanted defibrillator or pacemaker&#xD;
&#xD;
          -  Severe peptic ulcer disease, severe gastroesophageal reflux disease, or other severe&#xD;
             gastric acid hypersecretory conditions&#xD;
&#xD;
          -  Medical or surgical treatment that permanently alters gastric absorption (eg, gastric&#xD;
             or intestinal surgery). A history of cholecystectomy is not exclusionary.&#xD;
&#xD;
          -  History of prior allogeneic bone marrow progenitor cell or solid organ&#xD;
             transplantation.&#xD;
&#xD;
          -  Currently registered on an organ transplantation list.&#xD;
&#xD;
          -  History of bleeding from esophageal varices within 90 days prior to Admission (Day&#xD;
             -1).&#xD;
&#xD;
          -  Use of strong cytochrome P3A4 (CYP3A4) inhibitors (eg, indinavir, nelfinavir,&#xD;
             ritonavir, clarithromycin, itraconazole, ketoconazole, nefazodone, saquinavir,&#xD;
             suboxone, telithromycin, atazanavir) and strong CYP3A4 inducers (eg, carbamazepine,&#xD;
             rifampin, phenytoin and St. John's wort), within 28 days prior to study drug&#xD;
             administration (Day 1).&#xD;
&#xD;
          -  Consumption of grapefruit juice, grapefruits, and Seville orange juice within 2 weeks&#xD;
             prior to study drug administration (Day 1).&#xD;
&#xD;
          -  Recent significant changes in the use of nicotine or nicotine containing products&#xD;
&#xD;
        Participants with impaired hepatic function:&#xD;
&#xD;
          -  Aside from hepatic insufficiency, serious or active medical or psychiatric illness&#xD;
             that, in the opinion of the investigator, would interfere with treatment, assessment,&#xD;
             or compliance with the protocol.&#xD;
&#xD;
          -  Chronic hepatitis B virus (HBV) infection, defined as a positive test for hepatitis B&#xD;
             surface antigen (HBsAg), unless the participant has been treated with a nucleos(t)ide&#xD;
             analog (eg, tenofovir or entecavir) for at least 6 months and the HBV deoxyribonucleic&#xD;
             acid (DNA) by polymerase chain reaction (PCR) assay has been persistently undetectable&#xD;
             for at least 6 months.&#xD;
&#xD;
          -  Positive test for drugs of abuse, including alcohol at screening or on Day&#xD;
             -1/check-in, with the exception of opioids and tetrahydrocannabinol (THC, marijuana)&#xD;
             under prescription and investigator verification for pain management. Participants who&#xD;
             screen positive for benzodiazepines may be allowed if prescribed under the care of a&#xD;
             physician and after review by investigator and Sponsor.&#xD;
&#xD;
          -  Requires paracentesis &gt; 1 time per month.&#xD;
&#xD;
          -  Participants with hepatic impairment with co-morbid diseases not associated with&#xD;
             hepatic impairment requiring medication(s) must be taking the medication(s) without a&#xD;
             change in dose for &gt; 3 months prior to screening.&#xD;
&#xD;
          -  Changes in concomitant medications or dosage used to treat symptoms of hepatic&#xD;
             impairment or associated co-morbid conditions that could lead to clinically&#xD;
             significant changes in medical conditions during the course of the study that would&#xD;
             affect the ability to interpret potential drug-drug interactions within 28 days prior&#xD;
             to dosing.&#xD;
&#xD;
        Healthy participants (matched control):&#xD;
&#xD;
          -  A positive test result for hepatitis C virus (HCV) antibody, hepatitis B surface&#xD;
             antigen (HBsAg), or hepatitis B core antibody (anti-HBc)&#xD;
&#xD;
          -  Positive test for drugs of abuse, including alcohol at screening or on Day&#xD;
             -1/check-in.&#xD;
&#xD;
          -  Have any serious or active medical or psychiatric illness (including depression)&#xD;
             which, in the opinion of the investigator, would interfere with treatment, assessment,&#xD;
             or compliance with the protocol.&#xD;
&#xD;
          -  History of liver disease.&#xD;
&#xD;
          -  Have taken any prescription medications or over-the-counter medications including&#xD;
             herbal products within 28 days of commencing study drug dosing with the exception of&#xD;
             vitamins, acetaminophen, ibuprofen, and hormonal contraceptive medications.&#xD;
&#xD;
        Note: Other protocol defined Inclusion/Exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilead Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
    <country>New Zealand</country>
  </removed_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>July 16, 2015</study_first_submitted>
  <study_first_submitted_qc>July 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 28, 2015</study_first_posted>
  <results_first_submitted>January 7, 2021</results_first_submitted>
  <results_first_submitted_qc>January 7, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">January 27, 2021</results_first_posted>
  <last_update_submitted>January 7, 2021</last_update_submitted>
  <last_update_submitted_qc>January 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Selonsertib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled at study sites in United States. The first participant was screened on 17 August 2015. The last study visit occurred on 15 December 2015.</recruitment_details>
      <pre_assignment_details>107 participants were screened. In the control groups (normal hepatic function), each participant was matched for age, gender, race, and body mass index with a participant in the hepatic impairment group. 22 total unique participants with normal hepatic function were enrolled in Cohorts 1, 2, and 3. 3 participants served as matched control in both Cohort 1 and 2. 1 participant served as a matched control in both Cohort 1 and 3. 4 participants served as matched control in both Cohort 2 and 3.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cohort 1: Moderate Hepatic Impairment</title>
          <description>Participants with moderate hepatic impairment received a single oral dose of selonsertib 6 mg (1 × 6 mg tablet) in fed state on Day 1.</description>
        </group>
        <group group_id="P2">
          <title>Cohort 2: Severe Hepatic Impairment</title>
          <description>Participants with severe hepatic impairment received a single oral dose of selonsertib 6 mg (1 × 6 mg tablet) in fed state on Day 1.</description>
        </group>
        <group group_id="P3">
          <title>Cohort 3: Mild Hepatic Impairment</title>
          <description>Participants with mild hepatic impairment received a single oral dose of selonsertib 6 mg (1 × 6 mg tablet) in fed state on Day 1.</description>
        </group>
        <group group_id="P4">
          <title>Healthy Control</title>
          <description>Matched normal hepatic function participants received a single oral dose of selonsertib 6 mg (1 × 6 mg tablet) in fed state on Day 1.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The Safety Analysis Set included all enrolled participants who received at least 1 dose of study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>Cohort 1: Moderate Hepatic Impairment</title>
          <description>Participants with moderate hepatic impairment received a single oral dose of selonsertib 6 mg (1 × 6 mg tablet) in fed state on Day 1.</description>
        </group>
        <group group_id="B2">
          <title>Cohort 2: Severe Hepatic Impairment</title>
          <description>Participants with severe hepatic impairment received a single oral dose of selonsertib 6 mg (1 × 6 mg tablet) in fed state on Day 1.</description>
        </group>
        <group group_id="B3">
          <title>Cohort 3: Mild Hepatic Impairment</title>
          <description>Participants with mild hepatic impairment received a single oral dose of selonsertib 6 mg (1 × 6 mg tablet) in fed state on Day 1.</description>
        </group>
        <group group_id="B4">
          <title>Healthy Control</title>
          <description>Matched normal hepatic function participants received a single oral dose of selonsertib 6 mg (1 × 6 mg tablet) in fed state on Day 1.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="10"/>
            <count group_id="B4" value="22"/>
            <count group_id="B5" value="52"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59" spread="5.0"/>
                    <measurement group_id="B2" value="54" spread="5.8"/>
                    <measurement group_id="B3" value="53" spread="10.4"/>
                    <measurement group_id="B4" value="53" spread="8.4"/>
                    <measurement group_id="B5" value="54" spread="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetic (PK) Parameter: AUCinf of Selonsertib and Its Metabolite GS-607509</title>
        <description>AUCinf is defined as the concentration of drug extrapolated to infinite time.</description>
        <time_frame>0 (predose), 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96, and 120 hours postdose on Day 1. Additional PK samples were collected at the Day 10 and 14 follow-up visits approximately the same time as the Day 1 predose sample.</time_frame>
        <population>PK Analysis Set included all enrolled participants who received at least 1 dose of selonsertib and had at least 1 evaluable PK concentration data value reported by the PK laboratory for the respective analytes. 3 participants served as matched control in both Cohort 1 and 2. 1 participant served as a matched control in both Cohort 1 and 3. 4 participants served as matched control in both Cohort 2 and 3.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Moderate Hepatic Impairment</title>
            <description>Participants with moderate hepatic impairment received a single oral dose of selonsertib 6 mg (1 × 6 mg tablet) in fed state on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: Severe Hepatic Impairment</title>
            <description>Participants with severe hepatic impairment received a single oral dose of selonsertib 6 mg (1 × 6 mg tablet) in fed state on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: Mild Hepatic Impairment</title>
            <description>Participants with mild hepatic impairment received a single oral dose of selonsertib 6 mg (1 × 6 mg tablet) in fed state on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Matched Healthy Control for Cohort 1</title>
            <description>Matched normal hepatic function participants to moderate hepatic impairment received a single oral dose of selonsertib 6 mg (1 × 6 mg tablet) in fed state on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Matched Healthy Control for Cohort 2</title>
            <description>Matched normal hepatic function participants to severe hepatic impairment received a single oral dose of selonsertib 6 mg (1 × 6 mg tablet) in fed state on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Matched Healthy Control for Cohort 3</title>
            <description>Matched normal hepatic function participants to mild hepatic impairment received a single oral dose of selonsertib 6 mg (1 × 6 mg tablet) in fed state on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic (PK) Parameter: AUCinf of Selonsertib and Its Metabolite GS-607509</title>
          <description>AUCinf is defined as the concentration of drug extrapolated to infinite time.</description>
          <population>PK Analysis Set included all enrolled participants who received at least 1 dose of selonsertib and had at least 1 evaluable PK concentration data value reported by the PK laboratory for the respective analytes. 3 participants served as matched control in both Cohort 1 and 2. 1 participant served as a matched control in both Cohort 1 and 3. 4 participants served as matched control in both Cohort 2 and 3.</population>
          <units>hr*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUCinf of Selonsertib</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3316.1" spread="1734.11"/>
                    <measurement group_id="O2" value="3266.7" spread="766.39"/>
                    <measurement group_id="O3" value="2962.1" spread="901.12"/>
                    <measurement group_id="O4" value="2835.3" spread="499.58"/>
                    <measurement group_id="O5" value="2277.9" spread="490.96"/>
                    <measurement group_id="O6" value="2711.6" spread="919.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUCinf of GS-607509</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5941.8" spread="2286.80"/>
                    <measurement group_id="O2" value="5711.2" spread="3401.94"/>
                    <measurement group_id="O3" value="10203.6" spread="8689.39"/>
                    <measurement group_id="O4" value="9993.3" spread="4599.91"/>
                    <measurement group_id="O5" value="9603.4" spread="8057.84"/>
                    <measurement group_id="O6" value="9846.6" spread="8954.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>AUCinf of selonsertib</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>%Geometric least-square mean(GLSM) ratio</param_type>
            <param_value>105.08</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>77.08</ci_lower_limit>
            <ci_upper_limit>143.23</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>AUCinf of selonsertib</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>% GLSM ratio</param_type>
            <param_value>142.65</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>120.52</ci_lower_limit>
            <ci_upper_limit>168.84</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>AUCinf of selonsertib</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>% GLSM ratio</param_type>
            <param_value>110.55</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>86.99</ci_lower_limit>
            <ci_upper_limit>140.49</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>AUCinf of GS-607509</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>% GLSM ratio</param_type>
            <param_value>62.05</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>43.84</ci_lower_limit>
            <ci_upper_limit>87.81</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>AUCinf of GS-607509</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>% GLSM ratio</param_type>
            <param_value>66.44</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>36.72</ci_lower_limit>
            <ci_upper_limit>120.21</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>AUCinf of GS-607509</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>% GLSM ratio</param_type>
            <param_value>103.46</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>51.75</ci_lower_limit>
            <ci_upper_limit>206.83</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PK Parameter: AUClast of Selonsertib and Its Metabolite GS-607509</title>
        <description>AUClast is defined as the concentration of drug from time zero to the last observable concentration.</description>
        <time_frame>0 (predose), 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96, and 120 hours postdose on Day 1. Additional PK samples were collected at the Day 10 and 14 follow-up visits approximately the same time as the Day 1 predose sample.</time_frame>
        <population>Participants in the PK Analysis Set were analyzed. 3 participants served as matched control in both Cohort 1 and 2. 1 participant served as a matched control in both Cohort 1 and 3. 4 participants served as matched control in both Cohort 2 and 3.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Moderate Hepatic Impairment</title>
            <description>Participants with moderate hepatic impairment received a single oral dose of selonsertib 6 mg (1 × 6 mg tablet) in fed state on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: Severe Hepatic Impairment</title>
            <description>Participants with severe hepatic impairment received a single oral dose of selonsertib 6 mg (1 × 6 mg tablet) in fed state on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: Mild Hepatic Impairment</title>
            <description>Participants with mild hepatic impairment received a single oral dose of selonsertib 6 mg (1 × 6 mg tablet) in fed state on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Matched Healthy Control for Cohort 1</title>
            <description>Matched normal hepatic function participants to moderate hepatic impairment received a single oral dose of selonsertib 6 mg (1 × 6 mg tablet) in fed state on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Matched Healthy Control for Cohort 2</title>
            <description>Matched normal hepatic function participants to severe hepatic impairment received a single oral dose of selonsertib 6 mg (1 × 6 mg tablet) in fed state on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Matched Healthy Control for Cohort 3</title>
            <description>Matched normal hepatic function participants to mild hepatic impairment received a single oral dose of selonsertib 6 mg (1 × 6 mg tablet) in fed state on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>PK Parameter: AUClast of Selonsertib and Its Metabolite GS-607509</title>
          <description>AUClast is defined as the concentration of drug from time zero to the last observable concentration.</description>
          <population>Participants in the PK Analysis Set were analyzed. 3 participants served as matched control in both Cohort 1 and 2. 1 participant served as a matched control in both Cohort 1 and 3. 4 participants served as matched control in both Cohort 2 and 3.</population>
          <units>hr*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUClast of Selonsertib</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2964.1" spread="1493.69"/>
                    <measurement group_id="O2" value="3032.7" spread="728.55"/>
                    <measurement group_id="O3" value="2790.8" spread="847.18"/>
                    <measurement group_id="O4" value="2679.9" spread="486.23"/>
                    <measurement group_id="O5" value="2129.7" spread="493.83"/>
                    <measurement group_id="O6" value="2530.9" spread="902.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUClast of GS-607509</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5405.2" spread="2211.86"/>
                    <measurement group_id="O2" value="4868.0" spread="3072.43"/>
                    <measurement group_id="O3" value="8475.8" spread="7165.86"/>
                    <measurement group_id="O4" value="9117.6" spread="4127.22"/>
                    <measurement group_id="O5" value="8157.5" spread="6019.61"/>
                    <measurement group_id="O6" value="8326.5" spread="6604.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>AUClast of selonsertib</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>% GLSM ratio</param_type>
            <param_value>99.87</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>73.38</ci_lower_limit>
            <ci_upper_limit>135.92</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>AUClast of selonsertib</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>% GLSM ratio</param_type>
            <param_value>141.75</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>118.50</ci_lower_limit>
            <ci_upper_limit>169.55</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>AUClast of selonsertib</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>% GLSM ratio</param_type>
            <param_value>112.24</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>87.69</ci_lower_limit>
            <ci_upper_limit>143.65</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>AUClast of GS-607509</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>% GLSM ratio</param_type>
            <param_value>61.20</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>43.06</ci_lower_limit>
            <ci_upper_limit>86.98</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>AUClast of GS-607509</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>% GLSM ratio</param_type>
            <param_value>61.07</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>33.62</ci_lower_limit>
            <ci_upper_limit>110.91</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>AUClast of GS-607509</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>% GLSM ratio</param_type>
            <param_value>96.13</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>48.47</ci_lower_limit>
            <ci_upper_limit>190.67</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PK Parameter: Cmax of Selonsertib and Its Metabolite GS-607509</title>
        <description>Cmax is defined as the maximum concentration of drug.</description>
        <time_frame>0 (predose), 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96, and 120 hours postdose on Day 1. Additional PK samples were collected at the Day 10 and 14 follow-up visits approximately the same time as the Day 1 predose sample.</time_frame>
        <population>Participants in the PK Analysis Set were analyzed. 3 participants served as matched control in both Cohort 1 and 2. 1 participant served as a matched control in both Cohort 1 and 3. 4 participants served as matched control in both Cohort 2 and 3.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Moderate Hepatic Impairment</title>
            <description>Participants with moderate hepatic impairment received a single oral dose of selonsertib 6 mg (1 × 6 mg tablet) in fed state on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: Severe Hepatic Impairment</title>
            <description>Participants with severe hepatic impairment received a single oral dose of selonsertib 6 mg (1 × 6 mg tablet) in fed state on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: Mild Hepatic Impairment</title>
            <description>Participants with mild hepatic impairment received a single oral dose of selonsertib 6 mg (1 × 6 mg tablet) in fed state on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Matched Healthy Control for Cohort 1</title>
            <description>Matched normal hepatic function participants to moderate hepatic impairment received a single oral dose of selonsertib 6 mg (1 × 6 mg tablet) in fed state on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Matched Healthy Control for Cohort 2</title>
            <description>Matched normal hepatic function participants to severe hepatic impairment received a single oral dose of selonsertib 6 mg (1 × 6 mg tablet) in fed state on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Matched Healthy Control for Cohort 3</title>
            <description>Matched normal hepatic function participants to mild hepatic impairment received a single oral dose of selonsertib 6 mg (1 × 6 mg tablet) in fed state on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>PK Parameter: Cmax of Selonsertib and Its Metabolite GS-607509</title>
          <description>Cmax is defined as the maximum concentration of drug.</description>
          <population>Participants in the PK Analysis Set were analyzed. 3 participants served as matched control in both Cohort 1 and 2. 1 participant served as a matched control in both Cohort 1 and 3. 4 participants served as matched control in both Cohort 2 and 3.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cmax of Selonsertib</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.7" spread="20.66"/>
                    <measurement group_id="O2" value="82.4" spread="10.63"/>
                    <measurement group_id="O3" value="110.6" spread="24.77"/>
                    <measurement group_id="O4" value="105.4" spread="22.13"/>
                    <measurement group_id="O5" value="91.9" spread="22.01"/>
                    <measurement group_id="O6" value="110.3" spread="23.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax of GS-607509</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.1" spread="15.01"/>
                    <measurement group_id="O2" value="31.2" spread="15.34"/>
                    <measurement group_id="O3" value="63.5" spread="31.42"/>
                    <measurement group_id="O4" value="62.3" spread="23.44"/>
                    <measurement group_id="O5" value="63.2" spread="27.03"/>
                    <measurement group_id="O6" value="64.2" spread="21.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Cmax of selonsertib</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>% GLSM ratio</param_type>
            <param_value>88.68</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>74.83</ci_lower_limit>
            <ci_upper_limit>105.10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Cmax of selonsertib</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>% GLSM ratio</param_type>
            <param_value>91.16</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>78.76</ci_lower_limit>
            <ci_upper_limit>105.52</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Cmax of selonsertib</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>% GLSM ratio</param_type>
            <param_value>100.19</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>83.73</ci_lower_limit>
            <ci_upper_limit>119.88</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Cmax of GS-607509</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>% GLSM ratio</param_type>
            <param_value>71.44</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>54.58</ci_lower_limit>
            <ci_upper_limit>93.50</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Cmax of GS-607509</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>% GLSM ratio</param_type>
            <param_value>46.92</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>32.59</ci_lower_limit>
            <ci_upper_limit>67.54</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Cmax of GS-607509</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>% GLSM ratio</param_type>
            <param_value>93.93</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>67.60</ci_lower_limit>
            <ci_upper_limit>130.50</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Experiencing Treatment-Emergent Study Drug-related Adverse Events (AEs)</title>
        <description>An AE was any untoward medical occurrence in a clinical study participant which did not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Treatment-emergent AEs were defined as events that met one of the following criteria: 1) Any AEs with an onset date of on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug; or 2) Any AEs leading to premature discontinuation of study drug.</description>
        <time_frame>Day 1 plus 30 days</time_frame>
        <population>The Safety Analysis Set included all enrolled participants who received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Moderate Hepatic Impairment</title>
            <description>Participants with moderate hepatic impairment received a single oral dose of selonsertib 6 mg (1 × 6 mg tablet) in fed state on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: Severe Hepatic Impairment</title>
            <description>Participants with severe hepatic impairment received a single oral dose of selonsertib 6 mg (1 × 6 mg tablet) in fed state on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: Mild Hepatic Impairment</title>
            <description>Participants with mild hepatic impairment received a single oral dose of selonsertib 6 mg (1 × 6 mg tablet) in fed state on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Healthy Control</title>
            <description>Matched normal hepatic function participants received a single oral dose of selonsertib 6 mg (1 × 6 mg tablet) in fed state on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Experiencing Treatment-Emergent Study Drug-related Adverse Events (AEs)</title>
          <description>An AE was any untoward medical occurrence in a clinical study participant which did not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Treatment-emergent AEs were defined as events that met one of the following criteria: 1) Any AEs with an onset date of on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug; or 2) Any AEs leading to premature discontinuation of study drug.</description>
          <population>The Safety Analysis Set included all enrolled participants who received at least 1 dose of study drug.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="10.0"/>
                    <measurement group_id="O4" value="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Experiencing Any Treatment-Emergent and Grade ≥ 3 Laboratory Abnormalities</title>
        <description>Treatment-emergent laboratory abnormalities were defined as values that increased at least 1 toxicity grade from predose at any postdose visit, up to and including the date of last dose of study drug plus 30 days for participants who permanently discontinued study drug. If the relevant baseline laboratory value was missing, then any abnormality of at least Grade 1 observed within the time frame specified above was considered treatment-emergent. Severity grades were defined based on modified Common Terminology Criteria for Adverse Events (CTCAE) Laboratory Abnormality and Adverse Event Severity Grading, where 1=Mild, 2=Moderate, 3=Severe, 4=Potentially Life Threatening. The most severe graded abnormality from all tests was counted for each participant.</description>
        <time_frame>Day 1 plus 30 days</time_frame>
        <population>Participants in the Safety Analysis Set were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Moderate Hepatic Impairment</title>
            <description>Participants with moderate hepatic impairment received a single oral dose of selonsertib 6 mg (1 × 6 mg tablet) in fed state on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: Severe Hepatic Impairment</title>
            <description>Participants with severe hepatic impairment received a single oral dose of selonsertib 6 mg (1 × 6 mg tablet) in fed state on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: Mild Hepatic Impairment</title>
            <description>Participants with mild hepatic impairment received a single oral dose of selonsertib 6 mg (1 × 6 mg tablet) in fed state on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Healthy Control</title>
            <description>Matched normal hepatic function participants received a single oral dose of selonsertib 6 mg (1 × 6 mg tablet) in fed state on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Experiencing Any Treatment-Emergent and Grade ≥ 3 Laboratory Abnormalities</title>
          <description>Treatment-emergent laboratory abnormalities were defined as values that increased at least 1 toxicity grade from predose at any postdose visit, up to and including the date of last dose of study drug plus 30 days for participants who permanently discontinued study drug. If the relevant baseline laboratory value was missing, then any abnormality of at least Grade 1 observed within the time frame specified above was considered treatment-emergent. Severity grades were defined based on modified Common Terminology Criteria for Adverse Events (CTCAE) Laboratory Abnormality and Adverse Event Severity Grading, where 1=Mild, 2=Moderate, 3=Severe, 4=Potentially Life Threatening. The most severe graded abnormality from all tests was counted for each participant.</description>
          <population>Participants in the Safety Analysis Set were analyzed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Treatment-Emergent Laboratory Abnormalities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.0"/>
                    <measurement group_id="O2" value="90.0"/>
                    <measurement group_id="O3" value="70.0"/>
                    <measurement group_id="O4" value="59.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade ≥ 3 Laboratory Abnormalities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0"/>
                    <measurement group_id="O2" value="40.0"/>
                    <measurement group_id="O3" value="10.0"/>
                    <measurement group_id="O4" value="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Day 1 plus 30 days</time_frame>
      <desc>The Safety Analysis Set included all enrolled participants who received at least 1 dose of study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>Cohort 1: Moderate Hepatic Impairment</title>
          <description>Participants with moderate hepatic impairment received a single oral dose of selonsertib 6 mg (1 × 6 mg tablet) in fed state on Day 1.</description>
        </group>
        <group group_id="E2">
          <title>Cohort 2: Severe Hepatic Impairment</title>
          <description>Participants with severe hepatic impairment received a single oral dose of selonsertib 6 mg (1 × 6 mg tablet) in fed state on Day 1.</description>
        </group>
        <group group_id="E3">
          <title>Cohort 3: Mild Hepatic Impairment</title>
          <description>Participants with mild hepatic impairment received a single oral dose of selonsertib 6 mg (1 × 6 mg tablet) in fed state on Day 1.</description>
        </group>
        <group group_id="E4">
          <title>Healthy Control</title>
          <description>Matched normal hepatic function participants received a single oral dose of selonsertib 6 mg (1 × 6 mg tablet) in fed state on Day 1.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:&#xD;
The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or&#xD;
The study has been completed at all study sites for at least 2 years</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gilead Clinical Study Information Center</name_or_title>
      <organization>Gilead Sciences</organization>
      <phone>1-833-445-3230 (GILEAD-0)</phone>
      <email>GileadClinicalTrials@gilead.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

